The deal to acquire the specialty pharmaceutical company Rottapharm is expected to bolster Meda’s consumer health care business. It follows Meda’s fending off of a takeover approach from the American drug maker Mylan earlier this year.

from DealBook» Mergers & Acquisitions http://ift.tt/1n62ncK
via IFTTT

Publicités